DUBLIN, Ireland, June 16, 2026
Jazz Pharmaceuticals plc has unveiled extensive late-breaking research at SLEEP 2026, presenting 11 new scientific analyses that further demonstrate the real-world impact of Xywav® (calcium, magnesium, potassium, and sodium oxybates) in patients living with narcolepsy and idiopathic hypersomnia (IH). The data provide important insights into individualized treatment approaches, long-term patient outcomes, and the potential cardiometabolic benefits associated with Xywav’s low-sodium formulation. As one of the largest collections of new evidence presented at the congress, the findings reinforce Jazz Pharmaceuticals’ commitment to advancing the understanding of rare sleep disorders while supporting more personalized and comprehensive treatment strategies. The latest research highlights how Xywav may improve not only core symptoms such as excessive daytime sleepiness and disrupted nighttime sleep but also broader health outcomes that influence long-term quality of life and cardiovascular well-being.
New Evidence Supports Personalized Xywav Treatment Strategies
Among the most significant presentations were new analyses from the Phase 4 DUET study, which evaluated individualized dosing strategies for patients with narcolepsy and idiopathic hypersomnia. Researchers demonstrated that Xywav’s flexible dosing options allow treatment regimens to be tailored to the unique efficacy and tolerability needs of each patient. Results showed that patients achieved stable individualized doses within approximately six weeks of treatment initiation, supporting a personalized approach to long-term disease management.
Additional findings from the Xywav REMS program, which included data from more than 13,000 patients, further validated the feasibility of individualized treatment optimization in real-world clinical practice. Investigators reported that Xywav’s oral solution formulation enables physicians to adjust treatment regimens based on patient-specific responses, helping improve symptom control while maintaining tolerability. These findings are particularly important given the complexity and variability of sleep disorders such as narcolepsy and idiopathic hypersomnia, where individualized care remains essential for maximizing treatment outcomes.
Low-Sodium Xywav Shows Potential Cardiometabolic Benefits
Advertisement
Another key focus of the late-breaking presentations was the potential impact of reduced sodium exposure on long-term cardiovascular and metabolic health. Patients with narcolepsy are known to face elevated risks of hypertension, cardiovascular disease, stroke, heart failure, and other cardiometabolic complications. New data from the Phase 4 XYLO study demonstrated that patients who transitioned from high-sodium oxybate therapies to Xywav reported meaningful improvements in symptoms associated with sodium and fluid imbalance, including edema, nocturia, and excessive sweating. In addition, a retrospective analysis of electronic health records identified favorable changes in biomarkers associated with cardiovascular and metabolic risk.
Researchers observed reductions in non-high-density lipoprotein cholesterol, triglycerides, and systolic blood pressure among certain patient groups following Xywav initiation. Improvements in HDL cholesterol levels were also reported. These findings suggest that Xywav’s low-sodium formulation may provide health benefits extending beyond symptom management, potentially supporting better long-term cardiovascular outcomes in patients requiring lifelong treatment.
Expanding Understanding of Rare Sleep Disorders
The extensive body of research presented at SLEEP 2026 reflects Jazz Pharmaceuticals’ ongoing investment in sleep medicine and rare neurological disorders. Narcolepsy and idiopathic hypersomnia are chronic, often debilitating conditions that significantly affect daily functioning, cognitive performance, professional productivity, and overall quality of life. While Xywav is already approved for the treatment of excessive daytime sleepiness and cataplexy in narcolepsy as well as idiopathic hypersomnia in adults, the new findings continue to expand understanding of how optimized treatment strategies can influence broader patient outcomes.
Researchers emphasized the importance of addressing both symptom control and long-term health considerations when managing these disorders. By combining flexible dosing options with a substantially reduced sodium burden, Xywav continues to emerge as a differentiated treatment option capable of supporting personalized care while potentially reducing cardiovascular risk factors. The latest SLEEP 2026 presentations further strengthen the clinical evidence supporting Xywav and reinforce Jazz Pharmaceuticals’ leadership in developing innovative therapies for patients living with rare sleep disorders.
Source: Jazz Pharmaceuticals press release
